LSB — LakeShore Biopharma Co Income Statement
0.000.00%
Last trade - 00:00- $34.17m
- $88.02m
- CNY614.96m
Annual income statement for LakeShore Biopharma Co, fiscal year end - March 31st, CNY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 257 | 503 | 687 | 573 | 615 |
| Cost of Revenue | |||||
| Gross Profit | 197 | 386 | 534 | 456 | 507 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 383 | 622 | 827 | 1,019 | 701 |
| Operating Profit | -126 | -119 | -139 | -446 | -86.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -174 | -101 | -144 | -455 | -101 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -192 | -106 | -145 | -433 | -100 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -192 | -106 | -145 | -433 | -100 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -208 | -237 | -283 | -433 | -100 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -22.4 | -25.4 | -30.5 | -31 | -3.97 |
| Dividends per Share |